High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Blood

• Publication date

  2016-10-20

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1182/blood-2016-02-701805PMID 27381905PMCID PMC5073184
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII.

  2016cited by this paper
• Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry.

  2015cited by this paper
• Six Amino Acid Residues in a 1200 Å2 Interface Mediate Binding of Factor VIII to an IgG4κ Inhibitory Antibody

  2015cited by this paper
• Impact of inhibitors on hemophilia a mortality in the United States

  2015cited by this paper
• Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII.

  2015cited by this paper
• Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on‐demand with bypass treatment

  2015cited by this paper
• High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.

  2014cited by this paper
• The diversity of the immune response to the A2 domain of human factor VIII.

  2013cited by this paper
• Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes.

  2013cited by this paper
• Hepatitis B and C Virus Infections Are Not Associated With Worse Clinical Outcomes After Autologous Stem Cell Transplantation: On Behalf Of The Adult Lymphoma Working Group Of The Japan Society For Hematopoietic Cell Transplantation (JSHCT)

  2013cited by this paper
• Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.

  2013cited by this paper
• Hemophilia A in the third millennium.

  2013cited by this paper
• Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen–deuterium exchange mass spectrometry

  2013cited by this paper
• Factor VIII C1 Domain Spikes 2092–2093 and 2158–2159 Comprise Regions That Modulate Cofactor Function and Cellular Uptake

  2013cited by this paper
• Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition

  2012cited by this paper
• Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.

  2012influential reference
• A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.

  2012cited by this paper
• Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain.

  2012influential reference
• Least-squares fit to a straight line when each variable contains all equal errors

  2011cited by this paper
• A membrane-interactive surface on the factor VIII C1 domain cooperates with the C2 domain for cofactor function.

  2011cited by this paper
• Evaluation of factor VIII pharmacokinetics and anti‐factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII

  2011cited by this paper
• Factor VIII C1 domain residues Lys 2092 and Phe 2093 contribute to membrane binding and cofactor activity.

  2009cited by this paper
• The factor VIII C1 domain contributes to platelet binding.

  2008cited by this paper
• Non‐classical anti‐factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model

  2008cited by this paper
• Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors.

  2008cited by this paper
• The binding sites for the very low density lipoprotein receptor and low-density lipoprotein receptor-related protein are shared within coagulation factor VIII

  2008cited by this paper
• General introduction and outline of the thesis

  2008cited by this paper
• VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.

  2007cited by this paper
• The humoral response to human factor VIII in hemophilia A mice

  2007cited by this paper
• Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.

  2007influential reference
• Basic aspects of inhibitors to factors VIII and IX and the influence of non‐genetic risk factors

  2006cited by this paper
• Analyzing a kinetic titration series using affinity biosensors.

  2006cited by this paper
• Articles on similar topics can be found in the following Blood collections

  2006cited by this paper
• A1 Subunit-mediated Regulation of Thrombin-activated Factor VIII A2 Subunit Dissociation*

  2006cited by this paper
• Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody

  2006influential reference
• Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII

  2006cited by this paper
• Structure and Function of the Factor VIII Gene and Protein

  2003cited by this paper
• Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group.

  2003cited by this paper
• Inhibitors: resolving diagnostic and therapeutic dilemmas

  2002cited by this paper
• Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model.

  2002cited by this paper
• In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.

  2001cited by this paper
• Multiple VH genes are used to assemble human antibodies directed toward the A3-C1 domains of factor VIII.

  2001cited by this paper
• A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.

  2000cited by this paper
• Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.

  1999cited by this paper
• The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.

  1997cited by this paper
• Slowed Release of Thrombin-cleaved Factor VIII from von Willebrand Factor by a Monoclonal and a Human Antibody Is a Novel Mechanism for Factor VIII Inhibition*

  1996cited by this paper
• Alcian blue-treated polystyrene microtitre plates for use in an ELISA to measure antibodies against synthetic peptides.

  1994cited by this paper
• Inhibition of human factor VIIIa by anti-A2 subunit antibodies.

  1994cited by this paper
• Derivation of specific antibody‐producing tissue culture and tumor lines by cell fusion

  1976cited by this paper
• Data Reduction and Error Analysis for the Physical Sciences

  1969cited by this paper

• Missense and nonsense mutations and inhibitor development in patients with hemophilia A and B

  2025cites this paper
• Patient anti-FVIII drug antibodies bind preferentially to a subset of FVIII covalent states

  2025cites this paper
• Persistent Splenic-Derived IgM Preferentially Recognize Factor VIIIA2 and C2 Domain Epitopes but Do Not Alter Antibody Production.

  2024cites this paper
• Management of perioperative bleeding in acquired hemophilia a secondary to melanoma: Case report

  2024cites this paper
• Pathogenic but sweet: factor VIII inhibitor hits the hot spot.

  2024cites this paper
• Coagulation Factor VIII: Biological Basis of Emerging Hemophilia A Therapies.

  2024cites this paper
• Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort

  2024cites this paper
• Structural basis for inhibition of coagulation factor VIII reveals a shared antigenic hot-spot on the C1 domain.

  2024cites this paper
• Binding of therapeutic Fc-fused factor VIII to the neonatal Fc receptor at neutral pH associates with poor half-life extension

  2024cites this paper
• Structure of coagulation factor VIII bound to a patient-derived anti–C1 domain antibody inhibitor

  2023cites this paper
• Structural and Thermodynamic Studies of Antibody Binding to Blood Coagulation Factor VIII

  2023cites this paper
• Mice possess a more limited natural anti-human Factor VIII antibody repertoire than humans that is produced disproportionately by marginal zone B cells.

  2023cites this paper
• Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner

  2023cites this paper
• The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.

  2023cites this paper
• Structural insights into blood coagulation factor VIII: Procoagulant complexes, membrane binding, and antibody inhibition

  2022cites this paper
• Oral tolerance to prevent anti-drug antibody formation in protein replacement therapies.

  2022cites this paper
• Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway

  2022cites this paper
• Removal of single‐site N‐linked glycans on factor VIII alters binding of domain‐specific monoclonal antibodies

  2021cites this paper
• Research advances in hydrogen–deuterium exchange mass spectrometry for protein epitope mapping

  2021cites this paper
• Structure of Blood Coagulation Factor VIII in Complex with an Anti-C1 Domain Pathogenic Antibody Inhibitor.

  2021cites this paper
• Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy.

  2021cites this paper
• Vascularized Microfluidics and Their Untapped Potential for Discovery in Diseases of the Microvasculature

  2021cites this paper
• Characterisation and application of recombinant FVIII‐neutralising antibodies from haemophilia A inhibitor patients

  2021cites this paper
• Factor VIII-antibody structure and membrane binding.

  2021cites this paper
• Measurement of coagulation factor antibody levels is useful for diagnosis and determining therapeutic efficacy in hemorrhagic patients with autoantibodies to coagulation factor VIII and factor V: results from a single center in Japan

  2021cites this paper
• Epitope Screening Using Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS): An Optimized Workflow for Accelerated Evaluation of Lead Monoclonal Antibodies

  2021cites this paper
• Epitope screening using Hydrogen/Deuterium Exchange Mass Spectrometry (HDX‐MS): An accelerated workflow for evaluation of lead monoclonal antibodies

  2021cites this paper
• Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors

  2021cites this paper
• Structural and Mutational Characterization of the Blood Coagulation Factor VIII C Domain Lipid Binding Interface

  2021influential citation
• The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development.

  2020cites this paper
• Factor VIII-driven changes in activated Factor IX explored by Hydrogen-Deuterium eXchange Mass Spectrometry.

  2020cites this paper
• The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain

  2020cites this paper
• Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients

  2020cites this paper
• Structural Studies of Complexes of Blood Coagulation Factor VIII

  2019cites this paper
• Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A

  2018cites this paper
• Elimination of factor VIII‐specific B cells by immunotoxins composed of a single factor VIII domain fused to Pseudomonas exotoxin A

  2018cites this paper
• Anti‐C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model

  2018cites this paper
• Comparative evaluation between the new methods and the current methods of laboratory diagnosis for hemophilia: integrative literature review

  2018cites this paper
• Structural Characterization of a Human/Porcine Chimeric FVIII Construct and an Improved Human Factor VIII Model and Progress Towards Determination of the FVIII C1 Domain In Complex With Inhibitory Antibodies

  2018cites this paper
• A discontinuous autoinhibitory module masks the A1 domain of von Willebrand factor

  2017cites this paper
• Toward functional assays for assessing the significance of anti‐ABO(H) alloantibodies

  2017cites this paper
• Factor VIII inhibitors: Advances in basic and translational science

  2017cites this paper
• Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.

  2017cites this paper
• Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

  2017influential citation
• Stratégies thérapeutiques contre la réponse immunitaire anti-Facteur VIII chez l'hémophile A : par modification de la structure du FVIII, par inhibition de la signalisation des lymphocytes B

  2017cites this paper
• New insights into Factor VIII immunogenicity - an innovative method for personalized Hemophilia diagnostics

  2017cites this paper
• Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL.

  2017cites this paper
• Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells

  2017cites this paper
• Inhibitory antibodies against factor VIII C1 domain.

  2016cites this paper